Free Trial
OTCMKTS:DNPUF

Sumitomo Pharma (DNPUF) Stock Price, News & Analysis

Sumitomo Pharma logo
$6.53 0.00 (0.00%)
As of 05/27/2025

About Sumitomo Pharma Stock (OTCMKTS:DNPUF)

Key Stats

Today's Range
$6.53
$6.53
50-Day Range
$4.00
$6.53
52-Week Range
$1.99
$6.53
Volume
N/A
Average Volume
461 shs
Market Capitalization
N/A
P/E Ratio
0.11
Dividend Yield
220.08%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. It has partnerships with Keio University; RIKEN; Kyoto University; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Sumitomo Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

DNPUF MarketRank™: 

Sumitomo Pharma scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Sumitomo Pharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sumitomo Pharma is 0.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.74.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sumitomo Pharma is 0.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.89.

  • Read more about Sumitomo Pharma's valuation and earnings.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Sumitomo Pharma has a short interest ratio ("days to cover") of 71153, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Sumitomo Pharma has recently decreased by 3.84%, indicating that investor sentiment is improving.
  • Dividend Yield

    Sumitomo Pharma pays a meaningful dividend of 1.27%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Sumitomo Pharma does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Sumitomo Pharma is 24.70%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Sumitomo Pharma's dividend.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Sumitomo Pharma has a short interest ratio ("days to cover") of 71153, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Sumitomo Pharma has recently decreased by 3.84%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Sumitomo Pharma this week, compared to 0 articles on an average week.
Receive DNPUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sumitomo Pharma and its competitors with MarketBeat's FREE daily newsletter.

DNPUF Stock News Headlines

Do You Believe In President Trump? Answer This 1 Question
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
See More Headlines

DNPUF Stock Analysis - Frequently Asked Questions

Sumitomo Pharma's stock was trading at $4.13 at the beginning of the year. Since then, DNPUF shares have increased by 58.1% and is now trading at $6.53.
View the best growth stocks for 2025 here
.

Shares of DNPUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
5/28/2025
Next Earnings (Estimated)
7/29/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:DNPUF
CIK
N/A
Fax
N/A
Employees
6,250
Year Founded
N/A

Profitability

Trailing P/E Ratio
0.11
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (OTCMKTS:DNPUF) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners